Phase I trial of Tuvusertib (M1774) initiated for solid tumors by EMD Serono and Merck KGaA
EMD Serono and Merck KGaA have initiated Phase I trial for Tuvusertib (M1774) in patients with metastatic or locally advanced unresectable solid tumors, assessing safety, tolerability, and early efficacy.